EnWave Initiates Transfer of Commercial-Scale powderREV(R) Machine to Major North American Enzyme Producer

EnWave Initiates Transfer of Commercial-Scale powderREV(R) Machine to Major 
North American Enzyme Producer 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: EnWave Corporation 
TSX VENTURE SYMBOL:  ENW
FRANKFURT SYMBOL:  E4U 
FEBRUARY 18, 2014 
EnWave Initiates Transfer of Commercial-Scale powderREV(R) Machine to Major
North American Enzyme Producer 
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 18, 2014) - EnWave Corporation
(TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave", or the
"Company") announced today that the Company has initiated the
transfer of a commercial-scale powderREV(R) machine (the "Machinery")
to the major North American enzyme producer (the "Enzyme Producer")
who signed a royalty-bearing commercial license to use Radiant Energy Vacuum
("REV(TM)") technology in April 2013. Prior to the initiation of the
transfer, EnWave completed successful in-house dehydration trials for several
enzyme solutions. 
EnWave will now begin installation of the machine at the Enzyme Producer's
site in preparation for initial testing to begin toward the beginning of April.
Complications relating to the Enzyme Producer's site preparation delayed
the timing of the delivery and the customer verification work which needs to be
completed with their established Tier 1 customers prior to commercialization.
If the customer verification is successful the Enzyme Producer and EnWave have
now targeted the second half of 2014 for commercial start-up of the Machinery.
The Enzyme Producer is expected to produce several dehydrated enzymes used in a
number of food related applications and has secured an option for another
enzyme category should the technology successfully meet commercial targets.  
powderREV(R) is designed with the goal of accelerating the drying times of
biomaterials below freezing, while reducing production costs and maintaining
high efficacy of the end product. Within the existing License Agreement, EnWave
has the right to showcase the commercial powderREV(R) plant to other potential
licensees in the future. The Enzyme industry is a large diverse growing global
market that produces applications for food products, detergents,
teeth-whitening products, biofuels and other health improvement areas. The
Company hopes to further penetrate this market after demonstrating initial
commercial success. 
"The interest in our commercial-scale powderREV(R) technology is at an
all-time high," stated Dr. Tim Durance, Chairman & Co-CEO. "We
are focused on doing everything in our power to expedite the start-up process,
which when completed will allow EnWave to showcase the Machinery to other
potential customers." 
About EnWave  
EnWave Corporation is a Vancouver-based industrial technology company
developing commercial applications for its proprietary Radiant Energy Vacuum
(REV(TM)) dehydration technology. EnWave aims to sign royalty-bearing
commercial licenses with leading food and pharmaceutical companies for the use
of its revolutionary technology. Thus far the Company has signed commercial
licenses with Bonduelle, a global leader in the production of vegetables, for
the processing of dehydrofrozen vegetables; Hormel Foods Corporation, a major
processed meat manufacturer, for the production of healthy dried meat products;
Milne Fruit Product, EnWave's first major licensee, for the production of
several dehydrated fruit and vegetable products in the whole, fragmented and
powdered form; a leading North American enzyme company, to dehydrate a series
of food-related enzymes for their Tier 1 clients; and Napa Mountain Spice
Company, to dry high-quality California bay leaves. In addition to these
licenses, EnWave has formed a Limited Liability Partnership with Lucid Capital
Management to develop, manufacture, market and sell all-natural cheese snack
products in the United States under the Moon Cheese(R) brand.  
Also, EnWave has entered into a wide range of research and collaboration
agreements with an expanding list of multinational companies, including Nestle,
Kellogg's, Grupo Bimbo, Grimmway Farms, Ocean Spray Cranberries, Cherry
Central, Sun-Maid Growers, Gay Lea Foods, R.J. Reynolds and Merck. EnWave is
introducing REV(TM) as a new dehydration standard in the food and biological
material sectors: potentially faster and cheaper than freeze drying, with
better end product quality than air drying or spray drying. 
EnWave currently has six REV(TM) platforms: commercial-scale nutraREV(R) and
MIVAP(R) are used in the food industry to dry fruits, vegetables, meat, herbs
and seafood quickly and at low-cost, while maintaining high levels of
nutrition, taste, texture and colour. The Company is also developing
powderREV(TM) for bulk dehydration of food cultures, probiotics and fine
biochemicals such as enzymes; quantaREV(TM) for continuous, high-volume
low-temperature drying of pastes, gels, liquids, or particulates; and
bioREV(TM) and freezeREV(TM) as new methods to stabilize and dehydrate
biopharmaceuticals such as vaccines and antibodies. More information about
EnWave is available at www.enwave.net.  
EnWave Corporation 
Dr. Tim Durance, Chairman & Co-CEO 
Safe Harbour for Forward-Looking Information Statements: This press release may
contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's
strategy for growth, product development, market position, expected
expenditures, and the expected synergies following the closing are
forward-looking statements. All third party references to market information in
this release are not guaranteed to be accurate as the Company did not conduct
the original primary research. These statements are not a guarantee of future
performance and involve a number of risks, uncertainties and assumptions.
Although the Company has attempted to identify important factors that could
cause actual results to differ materially, there may be other factors that
cause results not to be as anticipated, estimated or intended. There can be no
assurance that such statements will prove to be accurate, as actual results and
future events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements. 
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
EnWave Corporation
Mr. John McNicol
President & Co-CEO
(604)601-8524
or
EnWave Corporation
Mr. Brent Charleton
Vice President, Corporate Affairs
(778)378-9616
bcharleton@enwave.net 
INDUSTRY:  Medical and Healthcare - Alternative, Medical and Healthcare -
Dentistry, Medical and Healthcare - Mental Health, Medical and Healthcare -
Nursing, Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
Drugs 
SUBJECT:  BFC 
-0-
-0- Feb/18/2014 14:30 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.